TRAIL-CD28 armored anti-BCMA CAR-T cells

TRAIL-CD28 armored anti-BCMA CAR-T cells are next-generation, genetically engineered chimeric antigen receptor (CAR) T-cell therapies designed to treat multiple myeloma. Developed by researchers at the University of Calgary and Emory University, these autologous T cells are engineered to target B-cell maturation antigen (BCMA) on myeloma cells. To overcome resistance and enhance persistence, the CAR-T cells are armored with a chimeric TRAIL-CD28 fusion protein, which combines the extracellular and transmembrane domains of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with the intracellular signaling domain of CD28. This design allows the cells to engage death receptors (TRAIL-R1 and TRAIL-R2) on tumor cells to induce apoptosis, while simultaneously delivering a CD28-mediated pro-survival signal to the CAR-T cells. This dual mechanism mitigates TRAIL-induced fratricide, enhances T-cell fitness, and preserves a memory-like phenotype, showing potent preclinical efficacy against teclistamab-resistant and NFκB-activated multiple myeloma models.

Other names

TRAIL-CD28 armored anti-BCMA CAR-TTRAIL-CD-28 armored anti-BCMA CAR-TTRAIL-CD 28 armored anti-BCMA CAR-TTRAIL-CD28-armored anti-BCMA CAR-T cellsTRAIL-CD-28-armored anti-BCMA CAR-T cellsTRAIL-CD 28-armored anti-BCMA CAR-T cells